Markets
US ETF assets rise to $10.6 trillion
Sherwood News

Investors’ love affair with ETFs intensifies

US ETFs saw their assets swell to a record $10.6 trillion last year.

1/3/25 5:43AM

While individual stocks like Nvidia, Palantir, and Tesla dominated headlines in 2024, the titanic investment vehicles beneath the surface of the market — exchange-traded funds — quietly had a blockbuster year too. The Wall Street Journal reported that investors poured over $1 trillion into US ETFs last year through November, pushing their total assets to a record $10.6 trillion. That’s a 30% increase from the previous year and a more than fivefold surge over the past decade, data from research firm ETFGI showed.

Active versus passive

Obviously, it didn’t hurt that the stock market boomed. In 2024, the S&P 500 shattered 57 record highs, gaining 25%, while the tech-heavy Nasdaq soared 30%.

But the fast rise of ETFs is much more than a story about stock markets going up. It’s reflective of a decades-long transition from active to passive investing as traders eschew the traditional “hire someone smart and expensive to actively make my investing decisions for me” in favor of lower-cost passive options. And ETFs, which you can buy a slice of on an exchange, typically invest based on simple rules (track an index, buy assets that fit only X, Y, or Z criteria) and often have tax benefits, have boomed as a result.

These days, there are lots of whacky ETFs — and active ETFs are also growing rapidly — but the biggest ones in the US are still by far the simplest: they track America’s flagship S&P 500 Index. ETFs have been particularly successful in the States. In November alone, 97% of equity ETF inflows went to US stocks, as non-US markets continue to lag behind, according to State Street. Leading the pack in 2024 were large-cap ETFs tied to the S&P 500, followed by a bitcoin-focused fund and Invesco’s QQQ, which tracks the tech-heavy Nasdaq 100.

More Markets

See all Markets
markets

Tesla jumps after Elon Musk discloses buying 2.57 million shares, worth more than $1 billion

Tesla soared in early trading on Monday after CEO Elon Musk disclosed a purchase of 2.57 million shares in the company, according to a new SEC filing.

Per the filing, the "Elon Musk Revocable Trust,” for which the Tesla and SpaceX chief is the trustee, reported acquiring 2.57 million shares, taking its total ownership to 413.36 million shares as of September 12, 2025. The block of equity was bought at prices ranging from $371.38 to $396.54.

Investors are interpreting Musk's latest purchase — his first significant one since February 2020 — as a vote of confidence in the company. Tesla shares are now trading above their Dec. 31 closing price, making the stock positive for the year.

Earlier this month, the board of directors proposed an eye-watering pay package that could award the tech billionaire up to $1 trillion, assuming that very ambitious market cap and fundamental milestones are met.

markets

Hims & Hers falls after FDA commissioner says its Super Bowl ad breached regulations

Hims & Hers is falling in premarket trading after its Super Bowl ad from February was singled out as the “most overt” example of “brazen” marketing tactics among online pharmacies by FDA Commissioner Marty Makary.

The claim, made in an opinion piece written by Makary and published in the JAMA Network on Friday, highlighted the agency’s stricter enforcement policies on pharmaceutical advertisements.

“Equally brazen, online pharmacies are advertising drugs with only upsides mentioned, contributing to America’s culture of overreliance on pharmaceuticals for health,” wrote Makary. “This breach of FDA regulation was most overt earlier this year when Hims & Hers ran a Super Bowl ad highlighting the benefits of glucagon-like peptide-1 drugs without any mention of side effects or disclaimers.”

Hims’ Super Bowl ad touted its direct-to-consumer weight loss medications as “life-changing,” “affordable,” and “doctor-trusted,” billing its approach as “the future of healthcare.”

Google searches for the company spiked after the ad appeared during The Big Game.

Last week, President Donald Trump issued an executive order directing the Secretary of Health and Human Services to crack down on TV drug ads. It was initially unclear whether that order applied to telehealth companies.

Compounded drugs aren’t subject to the same regulatory burdens over their advertisements as branded, FDA-approved drugs made by pharmaceutical companies. For example, Hims can advertise generic Prozac for climax control (an off-label use) while the company that made the drug, Eli Lilly, cannot.

markets

Nvidia falls after Chinese regulator said it violated the country’s antitrust laws in 2020 deal

Nvidia dropped as much as 2.9% in early trading on Monday after China's State Administration for Market Regulation ruled that the chipmaker violated the country's antitrust laws after acquiring Mellanox Technologies, an Israeli-American network solutions supplier.

In 2020, Beijing approved Nvidia's ~$7 billion acquisition under the condition that the chipmaker would not discriminate against Chinese companies. Since then, Nvidia has had to redesign its chips to comply with the US government's regulations that temporarily banned the company from selling its advanced chips, including the H100.

Monday's preliminary finding from the SAMR comes amidst ongoing trade talks between US and Chinese officials in Madrid, with the tariff truce between the world's two largest economies set to expire in November.

As Sherwood’s Luke Kawa noted in August, China has appeared determined to “wean itself off of any dependence on Nvidia and US technology to develop its AI capabilities.”

According to Reuters, under Chinese antitrust law, companies can “face fines of between 1% and 10% of their annual sales from the previous year.” Nvidia’s sales in China generated $17.1 billion of revenue in its most recent fiscal year. Assuming the maximum penalty, the impact would be ~$1.7 billion, less than 1% of Wall Street’s forecast for Nvidia’s total revenue this fiscal year.

markets

Rocket lab soars to new record close amid rally for retail faves

Rocket Lab ripped by roughly 10% Friday to close at a new all-time high, riding an upturn of retail enthusiasm for a coterie of tech-themed favorites, even as the broader market was more or less flat on the day.

Goldman Sachs’ basket of “retail favorites” — its heaviest weights are Reddit, AppLovin, and Tempus AI — was the second-biggest gainer among the company’s flagship US equity baskets on Friday, rising about 1.6%. The S&P was almost dead flat.

It’s not Rocket Lab’s first retail rodeo, as the money-losing company has more than doubled this year and is up nearly 700% over the last 12 months.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.